Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 261

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 261
---
 $10.00 per Company Share (par value of $0.0001) and making a cash contribution in an amount of up to $10,000,000 that exceeds the aggregate amount of cash on deposit in the Trust Account (including any interest earned on the funds held in the Trust Account) remaining after payment in full of the SPAC Shareholder Redemption Amount. See “ Questions and Answers about the Business Combination and the Special Meeting — Q. What equity stake will our current shareholders and shareholders of the Target hold in OmnigenicsAI immediately after consummation of the Business Combination” and “ Certain Agreements Related to the Business Combination — Backstop Agreement.” On September8, 2023, APx issued the Working Capital Promissory Note in the principal amount of $500,000 to Templar Sponsor. The Templar Note does not bear interest and the principal balance will be payable on the Maturity Date, on which the Company consummates its initial business combination. In the event APx consummates its initial business combination, the Templar Sponsor has the option on the Maturity Date to convert up to $1,500,000 of the principal outstanding under the Templar Note into that number of Working Capital Warrants equal to the portion of the principal amount of the Templar Note being converted divided by $1.00, rounded up to the nearest whole number. The terms of the Working Capital Warrants, if any, would be identical to the terms of the private placement warrants issued by APx at the time of its initial public offering. On February9, 2024, the Company and Templar Sponsor entered into a Amended and Restated Note, pursuant to which the Working Capital Promissory Note was amended and restated, to increase the maximum principal amount from $500,000 to $2,000,000. As of December31, 2024, the fair value of these Working Capital Warrants is not significant, according to APx’s estimates. Therefore, any shares issuable under these Warrants were not considered for the purposes of this pro forma information.

116 The Special Meeting of SPAC Shareholders General APx is furnishing this proxy statement/prospectus to its shareholders as part of the solicitation of proxies by the APx Board for use at the Special Meeting to be held on, 2025, and at any postponements or adjournments thereof. This proxy statement/prospectus is first being furnished to APx’s shareholders on or about, 2025 in connection